LYRA — Lyra Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.34m
- -$15.56m
- $0.40m
Lyra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Lyra Therapeutics Reports Fourth Quarter Results
Lyra Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Lyra Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Trial Of LYR-220 In Post-Surgical Rhinosinusitis Patients
Brief: Lyra Therapeutics Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Lyra Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Lyra Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Lyra Therapeutics Inc - Audit Committee Of Board Of Co Says Prior Q1 And Q2 Financial Statements Should No Longer Be Relied Upon
Brief: Lyra Therapeutics Announces First Patient Enrolled In Pivotal Enlighten Ii Clinical Trial Of Lyr-210 In Chronic Rhinosinusitis Patients
Brief: Lyra Therapeutics To Present Additional Lantern Phase 2 Study Results At Ars Annual Meeting
Lyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Lyra Therapeutics reports Q2 results
Brief: Lyra Therapeutics Files For Offering Of Up To 15.5 Million Shares Common Stock
Lyra Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Lyra Therapeutics Reports First Quarter 2022 Financial Results And Provides Corporate Update
Lyra Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Lyra Therapeutics gains amid new data on nasal disease treatment
Brief: Lyra Therapeutics Presents Positive Data From Study Of LYR-210
Brief: Lyra Therapeutics Announces First Patient Treated In Phase 2 Beacon Clinical Trial Of Lyr-220 In Post-Surgical Chronic Rhinosinusitis Patients